The management of chronic gastric motility disorders has moved beyond simple dietary modifications toward a multi-modal therapeutic approach. The Gastroparesis Treatment Market is expanding as clinical focus intensifies on treating the underlying causes, such as diabetes-related autonomic neuropathy and post-surgical complications. Current pharmacological interventions primarily utilize prokinetic agents and antiemetics to stimulate stomach contractions and manage nausea.

However, the market is currently pivoting toward "Gastric Electrical Stimulation" (GES) and advanced surgical interventions like G-POEM (Gastric Peroral Endoscopic Myotomy). These technological advancements offer hope for patients who are refractory to traditional drug therapies. As research into the "gut-brain axis" deepens, new drug classes targeting specific serotonin receptors are entering clinical trials, aiming to provide more targeted relief with fewer cardiovascular side effects than earlier-generation prokinetics.